世界の医薬品原薬(API)市場展望...市場調査レポートについてご紹介

【英文タイトル】Global API Market Outlook 2018

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Analyst View
2. Research Methodology
3. APIs – An Introduction
4. Industry
4.1 Current and Future Market Analysis to 2018
5. Countries’ Comparative Analysis: API Manufacturing
5.1 Labor Cost and Productivity
5.2 Price Structure
5.3 Investment Cost in Plant Set-up
6. Key Geographical Markets
6.1 Americas
6.1.1 Current and Future Market
6.2 Asia
6.2.1 Current and Future Market
6.3 Europe
6.3.1 Current and Future Market
6.4 Others
7. Major Countries and their Regulatory Scenario
7.1 United States
7.1.1 Current and Future Market
7.1.2 Future Opportunity Assessment
7.2 Japan
7.2.1 Current and Future Market
7.2.2 Future Opportunity Assessment
7.3 Italy
7.3.1 Current and Future Market
7.3.2 Future Opportunity Assessment
7.4 China
7.4.1 Current and Future Market
7.4.2 Future Opportunity Assessment
7.5 India
7.5.1 Current and Future Market
7.5.2 Future Opportunity Assessment
7.6 South Korea
7.6.1 Current and Future Market
7.6.2 Future Opportunity Assessment
7.7 Others
8. Analysis by Therapeutic Segments
8.1 Central Nervous System Disorders
8.2 Cardiovascular Diseases
8.3 Diabetes
8.4 Respiratory Disorders
8.5 Oncology
9. Trends & Challenges
10. Competitive Landscape
10.1 BASF SE
10.2 Kyowa Hakko Kirin
10.3 North China Pharmaceutical Group Corporation
10.4 Teva Active Pharmaceutical Ingredients
10.5 Northeast Pharmaceutical Group
10.6 Lonza
10.7 Dr Reddy’s Laboratories
10.8 Zhejiang Hisun Pharmaceutical Co. Ltd.
10.9 Fabbrica Italiana Sintetici
10.10 Aurobindo Pharma Limited
10.11 Pfizer CentreSource
10.12 Divis Laboratories Limited
10.13 Cambrex Corporation
10.14 Royal DSM
10.15 Boehringer Ingelheim GmbH

List of Figures:

Figure 4-1: Global – API Market (Billion US$), 2013-2018
Figure 4-2: Global – Share of Captive and Merchant Market in API Market (2013)
Figure 4-3: Global – API Captive Market (Billion US$), 2013-2018
Figure 4-4: Global – API Merchant Market (Billion US$), 2013-2018
Figure 4-5: Global – Share of Branded and Generic APIs in API Merchant Market (2013)
Figure 4-6: Global – Generic API Merchant Market (Billion US$), 2013-2018
Figure 4-7: Global – Branded API Merchant Market (Billion US$), 2013-2018
Figure 4-8: Global – Share of Synthetic and Biotech APIs in API Market (2013)
Figure 5-1: Global – Price Structure for Pharmaceutical Fine Chemicals in US, India and China (%)
Figure 7-1: US – Pharmaceutical Sales (US$ Billion), 2013-2018
Figure 7-2: US – API Market (US$ Billion), 2013-2018
Figure 7-3: Japan – Pharmaceutical Sales (US$ Billion), 2013-2018
Figure 7-4: Japan – API Market (US$ Billion), 2013-2018
Figure 7-5: Italy – Pharmaceutical Sales (US$ Billion), 2013-2018
Figure 7-6: Italy – API Market (US$ Billion), 2013-2018
Figure 7-7: China- Pharmaceutical Sales (US$ Billion), 2013-2018
Figure 7-8: China- API Market (US$ Billion), 2013-2018
Figure 7-9: India Pharmaceutical Market (US$ Billion), 2013-2018
Figure 7-10: India – API Market (US$ Billion), 2013-2018
Figure 7-11: South Korea – Pharmaceutical Market (US$ Billion), 2013-2018
Figure 7-12: South Korea – API Market (US$ Billion), 2013-2018
Figure 7-13: Others – API Market (US$ Billion), 2013-2018
Figure 10-1: BASF SE – Break up of Revenue by Business Segment (%), 2013
Figure 10-2: BASF SE – Break up of Revenue by Geographic Segment (%), 2013
Figure 10-3: BASF SE – Chemicals – Break up of Revenue by Division (%), 2013
Figure 10-4: BASF SE – Intermediates- Break up of Revenue by Geographic Segment (%), 2013
Figure 10-5: Teva – Break up of Revenue by Geographical Segment (%), 2013
Figure 10-6: Teva – Break up of Revenue by Geographical Segment (%), 2013
Figure 10-7: Lonza – Break up of Revenue by Business Segment (%), 2013
Figure 10-8: Lonza – Break up of Revenue by Geographic Segment (%), 2013
Figure 10-9: DRL – Break up of Revenue by Business Segment (%), 2013
Figure 10-10: DRL – PSAI Break up of Revenue by Geographic Segment (%), 2013
Figure 10-11: Aurobindo Pharma Limited – Break up of Revenue by Business Segment (%), 2013
Figure 10-12: Aurobindo Pharma Limited – Break up of Revenue by Geographic Segment (%), 2013
Figure 10-13: Pfizer – Break up of Revenue by Business Segment (%), 2013
Figure 10-14: Pfizer – Break up of Revenue by Geographic Segment (%), 2013
Figure 10-15: Divis Laboratories – Break up of Revenue by Geographic Segment (%), 2013
Figure 10-16: Cambrex – Break up of Revenue by Geographic Segment (%), 2013
Figure 10-17: Royal DSM – Break up of Revenue by Business Segment (%), 2013
Figure 10-18: Royal DSM – Break up of Revenue by Geographic Origin (%), 2013
Figure 10-19: Boehringer – Break up of Revenue by Business Segment (%), 2013
Figure 10-20: Boehringer – Break up of Revenue by Geographic Segment (%), 2013

List of Tables:

Table 3-1: Classification of Bulk Drugs
Table 5-1: Global – Fine Chemical Industry Labor Cost and Productivity in Key Regions (2010)
Table 5-2: Global – Investment Cost Comparison for Multi-Purpose Pharmaceutical Fine Chemical Plants in Key Countries
Table 10-1: BASF SE – Key Financials (Million EUR), 2011-2013
Table 10-2: BASF SE- Strengths and Weaknesses
Table 10-3: Kyowa Hakko Kirin – Key Financials (Million Yen), 2011-2013
Table 10-4: Kyowa Hakko Kirin – Strengths and Weaknesses
Table 10-5: North China Pharmaceutical Group – Key Financials (Million Yuan), 2011-2013
Table 10-6: North China Pharmaceutical Group – Strengths and Weaknesses
Table 10-7: Teva Active Pharmaceutical Ingredients – Key Financials (Million USD), 2011-2013
Table 10-8: Teva Active Pharmaceutical Ingredients – Strengths and Weaknesses
Table 10-9: Northeast Pharmaceutical Group – Key Financials (Million Yuan), 2011-2013
Table 10-10: Northeast Pharmaceutical Group – Strengths and Weaknesses
Table 10-11: Lonza – Key Financials (Million CHF), 2011-2013
Table 10-12: Lonza – Strengths and Weaknesses
Table 10-13: DRL – Key Financials (Million Rupee), 2011-2013
Table 10-14: DRL – Strengths and Weaknesses
Table 10-15: Zhejiang Hisun Pharmaceutical – Key Financials (Million Yuan), 2011-2013
Table 10-16: Zhejiang Hisun Pharmaceutical – Strengths and Weaknesses
Table 10-17: Fabbrica Italiana Sintetici – Strengths and Weaknesses
Table 10-18: Aurobindo Pharma Limited – Key Financials (Million Rupee), 2011-2013
Table 10-19: Aurobindo Pharma Limited – Strengths and Weaknesses
Table 10-20: Pfizer – Key Financials (Million USD), 2011-2013
Table 10-21: Pfizer – Strengths and Weaknesses
Table 10-22: Divis Laboratories – Key Financials (Crore Rupee), 2011-2013
Table 10-23: Divis Laboratories Limited – Strengths and Weaknesses
Table 10-24: Cambrex – Key Financials (Million USD), 2011-2013
Table 10-25: Cambrex – Strengths and Weaknesses
Table 10-26: Royal DSM – Key Financials (Million EUR), 2011-2013
Table 10-27: Royal DSM – Strengths and Weaknesses
Table 10-28: Boehringer – Key Financials (Million EUR), 2011-2013
Table 10-29: Boehringer – Strengths and Weaknesses


【レポート販売概要】

■ タイトル:世界の医薬品原薬(API)市場展望
■ 英文:Global API Market Outlook 2018
■ 発行日:2014年8月
■ 調査会社:RNCOS
■ 商品コード:RNCS4088
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。